PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New drug shows potential for treating childhood neuroblastoma

Cancer Research UK-funded scientists have found a new drug that is likely to be effective against the aggressive childhood cancer neuroblastoma.

Neuroblastoma is a type of nerve tumour which is difficult to treat and often reoccurs after intensive treatment. Existing therapies for this type of cancer are particularly intense and have a profound impact on young patients and often cause long-term side effects.

Scientists at The Institute of Cancer Research, London, have discovered a new drug – fadraciclib – which is effective at blocking N-Myc activity.

Changes in the N-Myc gene occur in aggressive forms of neuroblastoma, making it a good target for treatment in this rare cancer type.

Fadraciclib has already passed safety trials in adults, and was jointly discovered by scientists at the ICR in collaboration with Cyclacel. The drug works by switching off the production of N-Myc.

In mice, the drug slowed down and stabilised tumour growth, and the mice who received it also survived for longer after treatment than untreated mice. When combined with chemotherapy in mice, the drugs shrank the tumours to the point of virtually eradicating them.

“I’m incredibly proud of the work our researchers have done to provide this hope for children with neuroblastoma,” said Michelle Mitchell, chief executive at Cancer Research UK.

“Children with aggressive cancer often go through gruelling treatments that, even when successful, may cause long-term side-effects. They still have their whole lives ahead of them, so it’s paramount to develop alternatives that won’t affect their quality of life in the long run,” she added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026